Onyx

Carrick bags ex-Onyx cancer drug, plans pivotal trials
Fierce Biotech
Thu, 10/11/18 - 09:27 am
ovarian cancer
Carrick
Onyx
CT900
Amgen's Focus On Kyprolis Data Shows Need To Aspire
Seeking Alpha
Sat, 08/17/13 - 10:41 am
Amgen
Kyprolis
Onyx
Hemerus Medical M&A
This Week in Biotech
Motley Fool
Sun, 08/11/13 - 10:57 am
Celgene
CompuGen
Bayer
Isis Pharmaceuticals
Onyx
Novo Nordisk
Amgen
Who Could Buy Onyx and at What Price?
Motley Fool
Sun, 07/14/13 - 11:21 am
Onyx
M&A
Amgen
Bayer
Celgene
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
Seeking Alpha
Wed, 04/24/13 - 10:19 am
Aveo Pharmaceuticals
FDA
tivozanib
GSK
Onyx
Pfizer
renal cell carcinoma
Roche
5 Can't-Miss Health-Care Events This Week
Motley Fool
Sun, 02/24/13 - 02:29 pm
Onyx
Bayer
Zogenix
Ariad
Questcor
Medivation
Which Companies Are In Michael King's Oncology Wheelhouse?
Seeking Alpha
Sat, 01/12/13 - 10:44 am
Alnylam
Regulus
Isis Pharmaceuticals
SynaGeva BioPharma
Sarepta Therapeutics
Onyx
Celgene
Millennium
Takeda
Ariad Pharmaceuticals
Pharmacyclics
Astex
13 Biotech Stock Predictions for 2013
TheStreet.com
Wed, 01/2/13 - 12:18 pm
Eisai
Sarepta
Arena Pharmaceuticals
Amarin
Gilead
Biomarin
Onyx
Medivation
Achillion
Incyte
Cell Therapeutics
Celgene
NPS Pharmaceuticals
Aegerion
Roche
Biogen Idec
Ariad Pharmaceuticals
Alexza
Navidea
Aveo
2012 Biotech Stock Predictions: An Interim Report Card
TheStreet.com
Tue, 08/28/12 - 11:07 am
Cell Therapeutics
Momenta
Onyx
Amag Pharmaceuticals
Biomarin
M&A
Celgene
Seattle Genetics
Galena Biopharma
ImmunoCellular
Amgen
Celldex
Dendreon
GSK
Vical
Oncothyreon
Biogen Idec
Merck KGaA
Bristol-Myers Squibb
Allos
Spectrum Pharmaceuticals
AstraZeneca
3 Innovative Biotech Stocks To Consider Today
Seeking Alpha
Mon, 08/13/12 - 01:36 pm
Celgene
OncoSec
Onyx
Bayer
Arqule
Pluristem's Cell Therapy For Bone Marrow A Blockbuster In The Making
Seeking Alpha
Wed, 08/8/12 - 12:04 pm
Pluristem
Amgen
AstraZeneca
Celgene
Dendreon
Eli Lilly
Medivation
Merck
Onyx
Pfizer
bone marrow disorder
Onyx’s Cancer Drug’s Risk May Outweigh Benefit, FDA Says
Bloomberg
Mon, 06/18/12 - 11:04 am
FDA
Onyx
Kyprolis
Multiple Myeloma
4 Companies With Upcoming Drug Approval Dates With 1 Potential Buyout Looming
Seeking Alpha
Fri, 06/15/12 - 10:10 am
Onyx
Carfilzomib
Arena Pharmaceuticals
lorcaserin
Vivus
Qnexa
AMR101
Amarin
Obagi Medical Products
Cell Therapeutics' JAK2 Inhibitor Acquisition Is A Smart Pick-Up
Seeking Alpha
Tue, 05/29/12 - 05:09 pm
Cell Therapeutics
JAK inhibitors
Novartis
Pfizer
Onyx
Incyte
pacritinib
ASCO Stocks To Consider This Week
Seeking Alpha
Tue, 05/29/12 - 11:15 am
ASCO
Arena Pharmaceuticals
Vivus
JNJ
Bayer
Onyx
Pharmacyclics
Onyx Pharma shares rise as analyst says sales of myeloma drug could reach $1B a year by 2016
Yahoo/AP
Fri, 05/25/12 - 11:18 am
Onyx
myeloma
Kyprolis
Nexavar: Are 3 Failed Phase 3 Trials Enough?
Motley Fool
Thu, 05/24/12 - 10:13 am
Bayer
Onyx
Nexavar
lung cancer
Bayer, Onyx cancer treatment Nexavar falls short of main goal in late-stage lung cancer study
Yahoo/AP
Tue, 05/22/12 - 09:42 am
Bayer
Onyx
Nexavar
lung cancer
Who’s on Biotech’s Endangered Species List? Mid-Sized Drugmakers
Xconomy
Mon, 05/21/12 - 12:55 pm
Regeneron
Illumina
Vivus
Seattle Genetics
Cubist Pharmaceuticals
Onyx
Outlooks for Pfizer, Arena and Onyx Following Busy May
TheStreet.com
Mon, 05/21/12 - 12:28 pm
Pfizer
Arena Pharmaceuticals
Onyx
lorcaserin
JAK3 inhibitors
Merck
Carfilzomib

Pages